Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Ye Hua
Ye Hua
BioNova Pharmaceuticals

Ye Hua, MD, MPH is the founder and CEO of BioNova Pharmaceuticals, a start-up biotech company that is focused on new drug development and regulatory registration to fill the gap of unmet medical needs in oncology and other diseases. Prior to building up BioNova, he was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharm, a leading R&D company in oncology and autoimmune diseases. Managing the clinical and regulatory organization, Dr. Hua is responsible for advancing clinical development pipeline and registering new drugs in China and ex-China. Under his leadership, the clinical development programs have grown from 5 small molecules in 7 Phase 1 oncology clinical trials to 8 small molecules in over 30 Phase 1-3 clinical trials in oncology and immunology in China, Australia, and the USA. Most recently, Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH policy and received NMPA approval. Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He worked as a cancer epidemiologist at Shanghai Cancer Institute between 1992 and 1996, and then went to McGill University in Montreal Canada to pursue a Master Degree in cancer epidemiology. Dr. Hua is a senior clinical research physician who has over seventeen years’ global clinical development and new drug registration experience in the pharmaceutical industry. He started his career in the pharmaceutical industry as a biostatistician at Pharmacia & Upjohn in 1999, and worked through the rank in biostatistics. His most significant achievement being the statistical team leader for the pivotal Phase 3 RA registration trial of Humira that won regulatory approval in the US and EU. Often contributed to clinical programs beyond his role in statistics, Dr. Hua was well recognized and greatly appreciated by cross-functional development teams. In 2004, one year after joining Novartis, Dr. Hua successfully switched career track back to clinical. Being a medical monitor, he led a number of global Phase II/III registration trials in osteoarthritis, osteoporosis, infectious diseases, oncology and hematology disease areas. As clinical project leader, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. His last job in the US was Senior Director, Global Clinical Development, Celgene Corporation where he led several global clinical teams for Revlimid and Pomalyst NDA/sNDA in multiple myeloma indication, and eventually obtained regulatory approval in the US and EU. In addition, he led clinical subteam executed registration trials for Revlimid and Pomalyst in China, and successfully obtained Revlimid regulatory approval in multiple myeloma indication.

Allied Academies Global Conference Directory

Copyright © 2018-2019 Allied Academies, All Rights Reserved.